A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 ?g of OPN-375 Twice a Day (BID) in Subjects with Chronic Sinusitis With or Without the Presence of Nasal PolypsOptiNose intends to study the efficacy and safety of OPN-375 in subjects with chronic sinusitis. Protocol #: 18-2823 Location: University of Colorado Hospital |
A PROSPECTIVE, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 EFFICACY AND SAFETY STUDY OF OTO-104 GIVEN AS A SINGLE INTRATYMPANIC INJECTION IN SUBJECTS WITH UNILATERAL MENIERE'S DISEASEParticipants will come into the clinic for 5 visits which will last 1.5-3.5 hours long. Each visit has an Audiologist and an Otologist component in it. Each participant will need to complete daily diary entries by calling into phone number and answering some questions. Protocol #: 18-1269 Location: University of Colorado Hospital |
Post Approval Study: Longitudinal Monitoring of Newly Implanted Subjects with the Nucleus Hybrid L24 Cochlear Implant SystemThe visit dates for this study are a candidacy evaluation, a baseline evaluation, the Initial Activation, 3 months, 6 months, 1 year, 2 years, 3 years, 4 years, and 5 years. Most of these visits will be at the same time as your clinical audiologist visits. To evaluate the long term safety and effectiveness of the Nucleus Hybrid L24 Implant in a group of newly implanted individuals Protocol #: 14-1927 Location: University of Colorado Hospital |